For Immediate Release

Company name: DAIICHI SANKYO COMPANY, LIMITED
Representative: Joji Nakayama, Representative Director, President and CEO
(Code no.: 4568, First Section, Tokyo Stock Exchange)
Please address inquiries to Noriaki Ishida, Executive Officer,
Vice President, Corporate Communications Department
Telephone: +81-3-6225-1126
http://www.daiichisankyo.com

Daiichi Sankyo Obtains Approval in Japan for Supplementary Indication of New Quinolone
Antibacterial Injection, “Cravit® Intravenous Drip Infusion”

Tokyo, Japan (September 24, 2015) - Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it has obtained approval for partial changes concerning a supplementary indication of their new quinolone antibacterial injections, Cravit® Intravenous Drip Infusion Bag 500mg/100mL and Cravit® Intravenous Drip Infusion 500mg/20mL (generic name: Levofloxacin Hydrate) to treat bacterial infections of urology, surgery, and gynecology.

These injections are broad-spectrum antibiotics for single-dose daily administration against Gram-positive and -negative bacteria and atypical pathogens. They will be indicated for the treatment of newly approved conditions in addition to respiratory infections, thereby increasing the indications (excluding peritonitis for which an oral agent is not indicated) for switch therapy from injection to oral medicine with the same active ingredient.

Daiichi Sankyo aims to contribute further in the field of medicine by providing new therapeutic options to patients and medical professionals through its Cravit® Intravenous Drip Infusion injections.
**Product Overview**

| Product Name | Cravit® Intravenous Drip Infusion Bag 500mg/100mL  
Cravit® Intravenous Drip Infusion 500mg/20mL |
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Generic name (JAN)</td>
<td>Levofloxacin Hydrate</td>
</tr>
<tr>
<td>Approval date for partial modification</td>
<td>September 24, 2015</td>
</tr>
<tr>
<td>Indication (additional content underlined)</td>
<td></td>
</tr>
</tbody>
</table>
  - **<Bacterial species>**
  - Levofloxacin-susceptible Staphylococcus sp., Streptococcus sp.,
    Streptococcus pneumoniae, Enterococcus sp., Moraxella (Branhamella) catarrhalis,
    Bacillus anthracis, Escherichia coli, Salmonella typhi, Salmonella paratyphi,
  
  - **<Indications>**
  - Secondary infections after trauma, burns, and surgical wounds, pneumonia, secondary infections in chronic respiratory lesions, cystitis, pyelonephritis, prostatitis (acute and chronic prostatitis), epididymitis, peritonitis, cholecystitis, cholangitis, typhoid, paratyphoid, intrauterine infection, uterine adnexitis, bacillus anthracis, brucellosis, plague, tularemia, and Q fever |